Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Animation Study Moving Forward After FDA Rejects Merck Critique

Executive Summary

Merck contends FDA's study of animation in drug ads may be ‘unnecessary for the proper performance of FDA’s functions’ but agency says it could influence policy.

Advertisement

Related Content

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
TV Drug Advertising Study Targets Those With Limited Or No Internet Use
Twitter Rx Drug Promos: FDA Studies Best Way To Convey Risk Info
DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size
DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel